Neuroleptic Malignant Syndrome and Related Conditions Second Edition PDF
Neuroleptic Malignant Syndrome and Related Conditions Second Edition PDF introduction of antipsychotic
drugs in the mid-1950s revolutionized the treatment of schizophrenia and
other psychotic disorders, allowing many patients in chronic hospital set-
tings to return to the community.
Neuroleptic Malignant Syndrome and Related Conditions Second Edition PDF antipsychotics do not cure
schizophrenia, they have decreased the disability and suffering associated
with this disorder and have enabled many patients to enjoy more indepen-
dent and productive lives. Shortly after antipsychotics came into clinical
use, it became apparent that they had numerous undesirable side effects.
Fortunately, most side effects are mild. Some rare side effects, however, are
associated with significant discomfort, disability, or even death.
Neuroleptic malignant syndrome (NMS) was first described in France
during early clinical trials of antipsychotics. However, it remained obscure and largely unrecognized in the English language literature until the 1980s.
By 1986, more than 300 cases of NMS had been reported. Also in 1986, the
term neuroleptic malignant syndrome was included as a specific medical head-
ing in Index Medicus. However, in our work with NMS during this period,
we found that most clinicians were unaware of or had only a limited appre-
ciation of this disorder. Furthermore, the topic had been largely neglected
in psychiatry texts of that era. “Reading up on NMS” meant culling the
American and foreign literature and, at best, obtaining information in a
Neuroleptic Malignant Syndrome and Related Conditions Second Edition PDF, it seemed to us that investigators familiar withNMS were beginning to develop meaningful strategies for recognizing, di-
agnosing, and treating this disorder; these strategies could prove critical in
avoiding a fatal outcome.